

Foretinib

Foretinib (GSK1363089) is a synthetic small anticancer molecule developed by GlaxoSmithKline after synthesis by Exelixis. Potently and ATP-competitively inhibits MET and VEGFR2 (IC₅₀=0.4 and 0.9nM, respectively), kinase enzymes believed to promote tumor growth and angiogenesis. Currently in phase 1b/2 clinical trials for breast cancer and NSCLC.

Materials Provided

Catalog Number:	92-1238
Quantity Supplied:	1 vial(s), 5 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	632.65 g/mol
Source:	Synthetic
Purity:	≥ 97%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	-20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	10 mM
Reconstitution Volume:	0.79 mL
Reconstitution Solvent:	DMSO

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com